Form 4: Sionna Therapeutics Director Sells Shares
Statement of Changes in Beneficial Ownership
Sionna Therapeutics Director Peter A. Thompson reported a sale of 115,844 shares of common stock on June 30, 2026, executed under a Rule 10b5-1 trading plan.
Summary
- Peter A. Thompson, a Director at Sionna Therapeutics, Inc., sold 115,844 shares of common stock on June 30, 2026.
- The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, designed to comply with affirmative defense conditions for the purchase or sale of equity securities.
- Following the sale, Thompson beneficially owns 2,555,877 shares.
- The sale was executed at a price of $45.50 per share.
- The securities are held indirectly through OrbiMed Private Investments VIII, LP, with OrbiMed Capital GP VIII LLC and OrbiMed Advisors LLC also having potential beneficial ownership and control.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the director's sale of a substantial number of shares, despite the transaction being conducted under a Rule 10b5-1 plan.
Negatives
- Director Peter A. Thompson sold a significant number of shares (115,844).
Future Outlook
No specific future outlook or guidance is provided in this filing, as it pertains to a transaction by a director.
Industry Context
StockSavvy.ai notes that insider sales, especially those executed under Rule 10b5-1 plans, are common disclosures. While not inherently negative, significant sales by directors can sometimes be interpreted by the market as a signal of reduced confidence, though the 10b5-1 plan structure is designed to mitigate this perception by establishing a pre-determined trading strategy.
Stakeholder Impact
- Shareholders may view the sale by a director with some concern, although the use of a 10b5-1 plan is intended to mitigate negative interpretations.
- The sale does not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 06/30/2026 | Transaction Date for sale of common stock. |
| 07/02/2026 | Date of signature for the filing. |
Keywords
Sionna Therapeutics, Peter A. Thompson, Form 4, SEC Filing, Stock Sale, Insider Trading, Rule 10b5-1, Beneficial Ownership, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.